The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Articles|May 2, 2020
- Pharmaceutical Technology-05-02-2020
- Volume 44
- Issue 5
Pharmaceutical Technology North America, May 2020 (PDF)
Click the title above to open the Pharmaceutical Technology May 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 6 years ago
Modern Drug Manufacturing Key to COVID-19 Responseover 6 years ago
How Fast Is Too Fast?over 6 years ago
Starting a Career in the Bio/Pharmaceutical Industryover 6 years ago
Can We Teach an Old Drug New Tricks?over 6 years ago
Good Manufacturing Practices: Aseptic and Sterile Processingover 6 years ago
Small-Volume Conversion Kit for Bathless Dissolution Testersover 6 years ago
Inline High Shear Mixersover 6 years ago
Pre-Packed ColumnsAdvertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement